GH Research PLC (NASDAQ:GHRS) Sees Large Increase in Short Interest

GH Research PLC (NASDAQ:GHRS) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 1,320,000 shares, a growth of 12.8% from the May 31st total of 1,170,000 shares. Currently, 4.3% of the company’s stock are sold short. Based on an average daily volume of 73,500 shares, the days-to-cover ratio is presently 18.0 days.

Hedge Funds Weigh In On GH Research

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Lynx1 Capital Management LP boosted its stake in GH Research by 80.1% in the first quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock valued at $35,291,000 after acquiring an additional 1,471,946 shares during the period. RA Capital Management L.P. boosted its stake in GH Research by 11.9% in the first quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after acquiring an additional 664,381 shares during the period. BVF Inc. IL boosted its stake in GH Research by 12.1% in the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares during the period. AdvisorShares Investments LLC boosted its stake in GH Research by 4.3% in the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after acquiring an additional 1,977 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of GH Research by 14.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after buying an additional 13,579 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Stock Up 1.2 %

GHRS stock traded up $0.14 during midday trading on Wednesday, reaching $12.05. The company had a trading volume of 37,787 shares, compared to its average volume of 103,273. The stock has a 50 day moving average price of $12.32 and a 200 day moving average price of $9.69. GH Research has a fifty-two week low of $5.05 and a fifty-two week high of $14.99. The firm has a market capitalization of $626.96 million, a PE ratio of -19.21 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last issued its earnings results on Friday, May 3rd. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Research analysts predict that GH Research will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Canaccord Genuity Group lifted their target price on GH Research from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, May 6th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Tuesday, May 7th.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).